m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT05940
|
[1] | |||
m6A modification
Lnc_D63785
Lnc_D63785
METTL3
Methylation
 : m6A sites
Indirect
Enhancement
Non-coding RNA
miR-422a
MEF2D
lncRNA miRNA circRNA
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | Methyltransferase-like 3 (METTL3) | WRITER | |||
| m6A Target | Lnc_D63785 | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | Non-coding RNA (ncRNA) | ||||
| Epigenetic Regulator | hsa-miR-422a | microRNA | View Details | ||
| Regulated Target | Myocyte enhancer factor 2D (MEF2D) | View Details | |||
| Crosstalk Relationship | m6A → ncRNA | Enhancement | |||
| Crosstalk Mechanism | m6A regulators indirectly modulate the functionality of ncRNAs through downstream signaling pathways | ||||
| Crosstalk Summary | Oxygen glucose deprivation/re-oxygenation (OGD/R) induces neuronal injury via mechanisms that are believed to mimic the pathways associated with brain ischemia. METTL3 shRNA reversed OGD/R-induced Lnc_D63785 m6A methylation to decrease hsa-miR-422a accumulation. The accumulation of the microRNA miR-422a leads to downregulation of miR-422a targets Myocyte enhancer factor 2D (MEF2D) and MAPKK6. | ||||
| Responsed Disease | Unspecific body region injury | ICD-11: ND56 | |||
| Pathway Response | Apoptosis | hsa04210 | |||
| Cell Process | Neuronal cell apoptosis | ||||
In-vitro Model |
SH-SY5Y | Neuroblastoma | Homo sapiens | CVCL_0019 | |
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
| ND56: Unspecific body region injury | 1 Compound(s) Regulating the Disease | Click to Show/Hide the Full List | ||
 Compound Name |
ONO-4819 | Discontinued in Phase 2 | [2] | |
|---|---|---|---|---|
| Synonyms |
Rivenprost; AE1-734; ONO-4819CD; ONO-4819.CD; ONO-AE1-734
Click to Show/Hide
|
|||
| External Link | ||||
References